GCG and metabolic syndrome: In summary, the studies reported here provide evidence of decreased LDL cholesterol and increased GLP-1 levels when using elobixibat in patients with dyslipidemia and with CC respectively; these effects are consistent with metabolic effects of BAs in the ileocolonic region in humans.